Massar Capital Management LP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA)

Massar Capital Management LP bought a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 202,674 shares of the company's stock, valued at approximately $8,427,000. Moderna makes up 9.6% of Massar Capital Management LP's investment portfolio, making the stock its largest position. Massar Capital Management LP owned 0.05% of Moderna as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of MRNA. Allworth Financial LP lifted its position in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. grew its position in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after buying an additional 297 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after buying an additional 345 shares during the period. Larson Financial Group LLC increased its stake in shares of Moderna by 39.1% during the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after buying an additional 356 shares during the period. Finally, New Insight Wealth Advisors lifted its stake in Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after acquiring an additional 358 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Trading Down 0.6 %

NASDAQ:MRNA traded down $0.17 during trading hours on Friday, hitting $27.22. The stock had a trading volume of 7,714,270 shares, compared to its average volume of 7,343,317. The business has a 50 day simple moving average of $30.36 and a two-hundred day simple moving average of $38.85. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The company has a market cap of $10.52 billion, a PE ratio of -2.93 and a beta of 2.23.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MRNA. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. Berenberg Bank upped their price objective on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Leerink Partners dropped their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Morgan Stanley reduced their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Finally, The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and dropped their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and an average price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.